Resolution of Inflammation
Novel Lipid Mediators Mediate Resolution of Inflammation.
Adapted from Serhan CN. The American Journal of
Acute pulmonary inflammation is a programmed response to inhaled injury that is intended to protect the host. The inflammatory response coordinates the entry of innate immune cells into injured tissue in order to mitigate the damage and initiate repair. On the other hand, failure to resolve inflammation can lead to a chronic inflammatory state, which in turn underlies important lung diseases like chronic obstructive pulmonary disease (COPD), asthma, and cancer. It is thus critical that the duration of pulmonary inflammation be precisely controlled. Long considered a passive process, the resolution of inflammation is now recognized as an active process mediated largely by specialized pro-resolving mediators (SPMs) derived from omega-3 and omega-6 polyunsaturated fatty acids.
Current research projects in the lab are focused on elucidating endogenous pro-resolving pathways in the lung, and exploring the therapeutic potential of SPMs for inflammatory lung diseases. Using cigarette smoke and other biologically-relevant exposures in both tissue culture and live animal models, we study the production of pro-resolving mediators within the lung, and the effects of exogenously administered SPMs on resolution. Techniques and areas of investigation: primary fibroblast isolation from patients, cell culture, preclinical animal models, cell biology, ELISA, western blot, lipidomics and immunohistochemical staining.